

# Daniel R Van Langenberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8934605/daniel-r-van-langenberg-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60  
papers

1,262  
citations

20  
h-index

34  
g-index

71  
ext. papers

1,512  
ext. citations

3.4  
avg, IF

4.62  
L-index

#	Paper	IF	Citations
60	Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2022</b> , 15, 17562848211070940	4.7	0
59	Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. <i>Research in Social and Administrative Pharmacy</i> , <b>2021</b> , 17, 1420-1425	2.9	1
58	Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy. <i>Intestinal Research</i> , <b>2021</b> ,	4.1	5
57	The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease. <i>Intestinal Research</i> , <b>2021</b> , 19, 158-170	4.1	2
56	Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 583-593	1.5	4
55	Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience - effective, safe, yet room for improvement. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 106-110	1.6	0
54	The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 369-379	4.5	2
53	A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1342-1352	6.1	4
52	Medical Management of Infliximab Failure in Acute Severe Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 1029	1.5	0
51	Aminosalicilate withdrawal following escalation to immunomodulators or biologics in ulcerative colitis: cost saving, convenient and does not compromise efficacy. <i>GastroHep</i> , <b>2020</b> , 2, 57-63	1	0
50	Inflammatory bowel disease and superior mesenteric artery thromboembolism. <i>Intestinal Research</i> , <b>2020</b> , 18, 130-133	4.1	0
49	Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 561-562	6.1	1
48	Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 564-565	6.1	1
47	Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1174-1184	6.1	6
46	Inflammatory Bowel Disease Helpline Reduces Subsequent Inpatient Admission Rates. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, 281	1.5	2
45	Letter: rationalising aminosalicylates in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1619-1620	6.1	
44	Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1462-1473	4.5	10

43	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Biologics <b>2019</b> , 243-255		0
42	A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab early colectomy. <i>Therapeutic Advances in Chronic Disease</i> , <b>2019</b> , 10, 2040622319825595	4.9	4
41	Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 94-100	1.6	7
40	Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 1622-1631	4	6
39	Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 289-297	1.5	24
38	Predicting response after infliximab salvage in acute severe ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1347-1352	4	24
37	Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 682-688	3.3	15
36	Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 226-231	4	7
35	Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease. <i>Journal of Crohns and Colitis</i> , <b>2018</b> , 12, 280-288	1.5	15
34	Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation). <i>JGH Open</i> , <b>2018</b> , 2, 217-222	1.8	5
33	Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it!. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1028-1029	6.1	1
32	Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1135-1145	6.1	29
31	Inflammatory Bowel Disease Clinical. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 121-154	4	8
30	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 1037-1053	6.1	165
29	Cognitive impairment in Crohn's disease is associated with systemic inflammation, symptom burden and sleep disturbance. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 579-587	5.3	27
28	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 6385-6402	5.6	31
27	Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 2966-2976	4.5	27
26	New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31 Suppl 1, 10-1	4	

25	Poor predictive value of breath hydrogen response for probiotic effects in IBS. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1731-9	4	9
24	Changing face of care for patients with moderate to severe inflammatory bowel disease: the role of specialist nurses in the governance of anti-TNF prescribing. <i>Internal Medicine Journal</i> , <b>2015</b> , 45, 1161-6	1.6	6
23	Sleep and physical activity measured by accelerometry in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 991-1004	6.1	37
22	Objectively measured muscle fatigue in Crohn's disease: correlation with self-reported fatigue and associated factors for clinical application. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 137-46	1.5	39
21	Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome. <i>Journal of Human Nutrition and Dietetics</i> , <b>2014</b> , 27 Suppl 2, 263-75	3.1	78
20	Factors associated with physical and cognitive fatigue in patients with Crohn's disease: a cross-sectional and longitudinal study. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 115-25	4.5	49
19	Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 626-34	1.5	39
18	Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: a small step for clinicians, a potentially large step for improving quality of care. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, e367-74	1.5	20
17	Chronic pain in inflammatory bowel disease: characteristics and associations of a hospital-based cohort. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1210-7	4.5	38
16	Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 2906-18	4.5	59
15	Inflammatory bowel disease serology in Asia and the West. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 6207-13	5.6	16
14	Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelines-based audit. <i>Internal Medicine Journal</i> , <b>2012</b> , 42, e84-8	1.6	5
13	A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , <b>2012</b> , 6, 302-10	1.5	78
12	A dedicated inflammatory bowel disease service quantitatively and qualitatively improves outcomes in less than 18 months: a prospective cohort study in a large metropolitan centre. <i>Frontline Gastroenterology</i> , <b>2012</b> , 3, 137-142	2.6	14
11	Satisfaction with patient-doctor relationships in inflammatory bowel diseases: examining patient-initiated change of specialist. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 2212-8	5.6	11
10	Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: the cocktail best avoided, not stirred. <i>Journal of Crohns and Colitis</i> , <b>2011</b> , 5, 469-72	1.5	18
9	Functional gastrointestinal disorders in inflammatory bowel disease: impact on quality of life and psychological status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 916-23	4	58
8	Systematic review: fatigue in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 131-43	6.1	132

7	Adverse clinical phenotype in inflammatory bowel disease: a cross sectional study identifying factors potentially amenable to change. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 1250-8	4	28
6	The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea. <i>Internal Medicine Journal</i> , <b>2010</b> , 40, 819-27	1.6	7
5	Un-promoted issues in inflammatory bowel disease: opportunities to optimize care. <i>Internal Medicine Journal</i> , <b>2010</b> , 40, 173-82	1.6	41
4	Are all symptoms in patients in IBD due to occult inflammation?. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 2703; author reply 2703-4	0.7	
3	The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience. <i>Journal of Crohns and Colitis</i> , <b>2010</b> , 4, 413-21	1.5	30
2	Inflammatory Bowel Disease, Clinical. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, A311-A321	4	4
1	Gastrointestinal: acute haemorrhage from a Dieulafoy lesion within a gastric diverticulum managed endoscopically. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 1891	4	4